Yesterday, the FDA approved updated COVID-19 vaccines from Pfizer PFE, Moderna MRNA and Novavax NVAX for the 2025-26 vaccination season. These shots are designed to target the LP.8.1 strain of the virus.
FDA Removes Mandate Requirement of COVID-19 Vaccines
Unlike the past few years, when the FDA granted blanket approvals for use of COVID-19 vaccines across the general population, this time the agency restricted access to high-risk groups. Health secretary Robert F. Kennedy Jr. posted on X that the vaccines will be made available to those patients “who choose them after consulting with their doctors.”
These changes were expected after the FDA had previously issued guidelines that tightened the standards for using COVID-19 vaccines earlier this year. Under the new policy, all vaccines are cleared for adults aged 65 and older. However, for those under 65, the vaccines are permitted only for individuals with underlying conditions that raise the risk of severe COVID-19.
Company-Specific Approvals
The FDA cleared Moderna’s two COVID-19 vaccines – the first-generation Spikevax and the recently approved next-generation refrigerator-stable version called mNexspike. While Spikevax is approved for at-risk individuals aged six months and older, mNexspike is allowed for use in those aged 12 years and older. The improved storage profile of mNexspike could help Moderna expand access outside major healthcare hubs. Shares of Moderna rose 1.5% yesterday, reflecting investor confidence in the company’s ability to retain broad coverage.
Pfizer’s Comirnaty is now approved for at-risk individuals aged five years and older. This represents a narrower label compared with previous seasons, when the vaccine was available for use in all individuals six months and older. The tighter approval was likely one reason shares of Pfizer fell nearly 1% following the decision.
Novavax’s protein-based vaccine Nuvaxovid is approved for at-risk individuals aged 12 years and older, offering the only non-mRNA alternative that may appeal to patients preferring traditional vaccine platforms. Shares of NVAX rose about 1%, likely because the approval came nearly in step with its larger peers — a contrast to prior years when the company faced longer delays.
Commercial Availability of the Updated Vaccines
PFE claims that it will begin shipping the updated formulation of Comirnaty “immediately,” while Moderna stated that its vaccines will be available “in the coming days.”
Novavax’s vaccine will be marketed by its partner Sanofi as part of an exclusive licensing deal signed last year.
Our Take
The updated framework aims to align U.S. policy with the global consensus, which generally limits routine booster recommendations to older adults and those at higher risk, rather than adopting a “one-size-fits-all” approach.
For manufacturers, the competitive dynamics are beginning to diverge. Moderna benefits from a broad pediatric label and the improved storage profile offered by mNexspike. Pfizer, meanwhile, faces some pressure as its label narrows compared with prior years. Novavax remains a niche player but continues to differentiate itself as the only non-mRNA option.
Overall, the COVID-19 vaccine market is transitioning into a smaller but more sustainable phase, where product differentiation and targeted access will play a larger role in shaping long-term opportunities for Pfizer, Moderna and Novavax.
Quantum Computing Stocks Set To Soar
Artificial intelligence has already reshaped the investment landscape, and its convergence with quantum computing could lead to the most significant wealth-building opportunities of our time.
Today, you have a chance to position your portfolio at the forefront of this technological revolution. In our urgent special report, Beyond AI: The Quantum Leap in Computing Power, you'll discover the little-known stocks we believe will win the quantum computing race and deliver massive gains to early investors.
Access the Report Free Now >>Pfizer Inc. (PFE) : Free Stock Analysis Report
Moderna, Inc. (MRNA) : Free Stock Analysis Report
Novavax, Inc. (NVAX) : Free Stock Analysis Report
This article originally published on Zacks Investment Research (zacks.com).
The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.
